{{Drugbox|
|IUPAC_name = 5-(Phenylcarbamoylimino)-3-(1-phenylpropan-2-yl)-5''H''-1,2,3-oxadiazol-3-ium-2-ide
| image= Mesocarb_chemical_structure.png
| width= 230
| CAS_number= 34262-84-5
| ATC_prefix=
| ATC_suffix=
| PubChem= 71932
| DrugBank=
| C=18 | H=18 | N=4 | O=2
| molecular_weight = 322.36 g/mol
| bioavailability=
| metabolism = hepatic
| elimination_half-life= 
| excretion = renal
| pregnancy_category =
| legal_status = Class C (UK), Schedule III (USA)
| routes_of_administration= Oral
}}

'''Mesocarb''' (Sidnocarb, Sydnocarb) is a [[stimulant]] drug which was developed in the [[USSR]] in the 1970s. <ref>Anokhina IP, Zabrodin GD, Svirinovskii IaE. Characteristics of the central action of sidnocarb. ''Zhurnal Nevropatologii i Psikhiatrii Imeni S S Korsakova''. 1974;74(4):594-602. (Russian) [http://www.ncbi.nlm.nih.gov/pubmed/4825943 PMID 4825943]</ref> It has been shown to act as a [[dopamine reuptake inhibitor]]<ref>Anderzhanova EA, Afanas'ev II, Kudrin VS, Rayevsky KS. Effect of d-amphetamine and sydnocarb on the extracellular level of dopamine, 3,4-dihydroxyphenylacetic acid, and hydroxyl radicals generation in rat striatum. ''Annals of the New York Academy of Sciences''. 2000 Sep;914:137-45. [http://www.ncbi.nlm.nih.gov/pubmed/11085316 PMID 11085316]</ref><ref>Gainetdinov RR, Sotnikova TD, Grekhova TV and Rayevsky KS. Effects of a psychostimulant drug Sydnocarb on rat brain dopaminergic transmission in vivo. ''European Journal of Pharmacology'' 1997 Dec 4;340(1):53-8. [http://www.ncbi.nlm.nih.gov/pubmed/9527506 PMID 9527506]</ref> which is slower acting but longer lasting and less neurotoxic than [[dextroamphetamine]].<ref>Afanas'ev II, Anderzhanova EA, Kudrin VS, Rayevsky KS. Effects of amphetamine and sydnocarb on dopamine release and free radical generation in rat striatum. ''Pharmacology, Biochemistry and Behavior''. 2001 Jul-Aug;69(3-4):653-8. [http://www.ncbi.nlm.nih.gov/pubmed/11509228 PMID 11509228]</ref>

Mesocarb is still used for a variety of applications,<ref>Witkin JM, Savtchenko N, Mashkovsky M, Beekman M, Munzar P, Gasior M, Goldberg SR, Ungard JT, Kim J, Shippenberg T, Chefer V. Behavioral, toxic, and neurochemical effects of sydnocarb, a novel psychomotor stimulant: comparisons with methamphetamine. ''Journal of Pharmacology and Experimental Therapeutics''. 1999 Mar;288(3):1298-310. [http://www.ncbi.nlm.nih.gov/pubmed/10027871 PMID 10027871]</ref> including counteracting the sedative effects of [[benzodiazepine]] drugs,<ref>Valueva LA and Tozhanova NM. Correction by Sydnocarb of side effects produced by tranquilizers of benzodiazepine series. ''Journal of Neurology, Neurosurgery and Psychiatry'' 1982; 9:92–97.</ref> increasing workload capacity and cardiovascular function,<ref>Vinar O, Klein DF, Potter WZ, Gause EM. A survey of psychotropic medications not available in the United States. ''Neuropsychopharmacology'' 1991;5:201</ref> treatment of [[ADHD]] and hyperactivity in children,<ref> Turova NF, Misionzhnik EIu, Ermolina LA, Aziavchik AV, Krasov VA. Excretion of monoamines, their precursors and metabolites in the hyperactivity syndrome in mentally defective children. ''Voprosy Meditsinskoi Khimii''. 1988 Jan-Feb;34(1):47-50. (Russian) [http://www.ncbi.nlm.nih.gov/pubmed/3369126 PMID 3369126]</ref><ref>Krasov VA. Sidnocarb treatment of young schoolchildren with the hyperdynamic syndrome. ''Zhurnal Nevropatologii i Psikhiatrii Imeni S S Korsakova''. 1988;88(8):97-101. (Russian) [http://www.ncbi.nlm.nih.gov/pubmed/3195293 PMID 3195293]</ref> as a [[nootropic]],<ref>Ganiev MM, Kharlamov AN, Raevskii KS, Guseinov DIa. Effect of sidnocarb on learning and memory. ''Biulleten Eksperimental Biologii i Meditsiny''. 1987 Oct;104(10):453-4. (Russian) [http://www.ncbi.nlm.nih.gov/pubmed/3676468 PMID 3676468]</ref> and as a drug to enhance resistance to extremely cold temperatures.<ref>Barer AS, Lakota NG, Ostrovskaia GZ, Shashkov VS. Pharmacologic correction of the effect of cold on man. ''Kosmicheskaia Biologiia i Aviakosmicheskaia Meditsina''. 1988 Nov-Dec;22(6):66-73. (Russian) [http://www.ncbi.nlm.nih.gov/pubmed/2906380 PMID 2906380]</ref><ref>Levina MN, Badyshtov BA, Gan'shina TS. Thermoprotector properties of a combination of sydnocarb with ladasten. ''Eksperimental'naia i Klinicheskaia Farmakologiia''. 2006 Jan-Feb;69(1):71-3. (Russian) [http://www.ncbi.nlm.nih.gov/pubmed/16579065 PMID 16579065]</ref> It is also listed as having [[antidepressant]] and [[anticonvulsant]] properties. 

Mesocarb is sold in Russia as 5 milligram tablets under the brand name Sydnocarb. Hydroxylated metabolites can be detected in urine for up to 10 days after consumption, reflecting a relatively long half-life.<ref>Shpak AV, Appolonova SA, Semenov VA. Validation of liquid chromatography-electrospray ionization ion trap mass spectrometry method for the determination of mesocarb in human plasma and urine. ''Journal of Chromatographic Science''. 2005 Jan;43(1):11-21. [http://www.ncbi.nlm.nih.gov/pubmed/15808002 PMID 15808002]</ref>

Mesocarb is almost unknown in the western world and is neither used in medicine or studied scientifically to any great extent outside Russia and other countries in the former Soviet Union. It has however been added to the list of drugs under international control and is illegal in most countries, despite its multiple therapeutic applications and the lack of significant abuse potential seen in clinical practice.<ref> Rudenko GM and Altshuler RA. Experimental and clinical study of Sydnocarb. ''Hung Pharmacotherapy'', 1978;124:150–154 (Russian) </ref>

== Chemistry ==

Mesocarb is a [[mesoionic]] [[sydnone imine]].

== References ==
<div class="references-small">
<references/>
</div>

[[ru:Сиднокарб]]

{{stimulants}}

[[Category:Stimulants]]
[[Category:Dopamine reuptake inhibitors]]